154 related articles for article (PubMed ID: 11564708)
1. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1.
Hennige AM; Lammers R; Höppner W; Arlt D; Strack V; Teichmann R; Machicao F; Ullrich A; Häring HU; Kellerer M
Endocrinology; 2001 Oct; 142(10):4441-7. PubMed ID: 11564708
[TBL] [Abstract][Full Text] [Related]
2. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
3. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
4. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
5. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins.
Qiao S; Iwashita T; Furukawa T; Yamamoto M; Sobue G; Takahashi M
J Biol Chem; 2001 Mar; 276(12):9460-7. PubMed ID: 11121408
[TBL] [Abstract][Full Text] [Related]
7. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
8. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
Kurokawa K; Iwashita T; Murakami H; Hayashi H; Kawai K; Takahashi M
Oncogene; 2001 Apr; 20(16):1929-38. PubMed ID: 11360177
[TBL] [Abstract][Full Text] [Related]
9. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
[TBL] [Abstract][Full Text] [Related]
10. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
[TBL] [Abstract][Full Text] [Related]
11. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
14. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
15. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
[TBL] [Abstract][Full Text] [Related]
16. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
17. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
18. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
[TBL] [Abstract][Full Text] [Related]
19. Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1.
Brockdorff J; Williams S; Couture C; Mustelin T
Eur J Immunol; 1999 Aug; 29(8):2539-50. PubMed ID: 10458769
[TBL] [Abstract][Full Text] [Related]
20. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
